A landmark $16M clinical trial led by Sylvester Comprehensive Cancer Center will assess AI's impact on radiologist performance in mammography screening.
Key Details
- 1PRISM is the first major randomized U.S. trial to study AI in breast cancer screening.
- 2Supported by a $16 million award from PCORI, the study spans hundreds of thousands of mammograms across six states.
- 3Seven academic medical centers, including UCLA and University of Miami, are participating.
- 4The trial uses Transpara by ScreenPoint Medical as the AI tool, integrated via Aidoc aiOS.
- 5Radiologists will remain in control of interpretations, with randomized assignment to AI-assisted or radiologist-only reads.
- 6Outcomes include cancer detection, recall rates, and perceptions of AI from both patients and clinicians.
Why It Matters
This large, multicenter trial could establish high-level evidence on the true value of AI assistance in real-world breast imaging, directly influencing clinical implementation, policy, and practice. Its patient-centered design and rigorous methodology will help clarify how—and for whom—AI can best improve breast cancer screening results.
Source
EurekAlert
Related News
•EurekAlert
AI Tool Predicts Financial Toxicity Risk in Cancer Patients
Researchers developed a machine learning model to proactively identify cancer patients at high risk of financial stress from treatment.
•EurekAlert
Mayo Clinic Showcases Imaging AI and Early Cancer Detection Advances at ASCO 2026
Mayo Clinic researchers will present over 30 studies at ASCO 2026, highlighting new advances in imaging AI, data science, and early cancer detection.
•EurekAlert
AI-Simulation Approach Achieves 90% Faster Brain MRI with Minimal Data
A simulation-based AI method can reconstruct brain MRI scans with only 10% of the usual data, greatly reducing scan times.